Chatbots are not a new concept, but have recently gained popularity and traction. Launched in late 2022, ChatGPT (Chat Generative Pre-Trained Transformer) is a web-based platform designed to simulate interactive conversations and deliver real-time data. It has quickly become a tool that provides instantaneous information that can be more focused than a Google search.1 We,…
The ACR to the CMS: What You Need to Know About Biosimilars and G2211
On May 23, Drs. Chris Phillips and Rebecca Shepherd, chairs of the ACR’s Committee on Rheumatologic Care and Insurance Subcommittee, respectively, and members of the ACR’s advocacy staff team met with officials from the Centers for Medicare & Medicaid Services to discuss concerns on underwater biosimilars and restrictions on billing G2211.
Methotrexate Shows Promise for Hand Arthritis
Methotrexate—an affordable, established drug for rheumatoid arthritis—may also be helpful for patients suffering from osteoarthritis (OA) of the hand, a recent study reports.1 Treatment of hand OA and inflammation with 20 mg of methotrexate for six months had a moderate, but potentially clinically meaningful, effect on reducing pain and stiffness in patients with symptomatic hand…
Pharmacy Benefit Managers Under Scrutiny
“When pharmacy benefit managers [PBMs] came into being 30 years ago, they were seen as an important component of the prescription distribution system [because] they could guide benefits and money between the patient, pharmacy and the manufacturer,” says Angus Worthing, MD, president of the Alliance for Transparent & Affordable Prescriptions (ATAP). Health insurance companies hire…
Government Affairs: A Marathon, Not a Sprint
Government Affairs Committee member Donald Miller, PharmD, reflects on the effects of rheumatology advocacy work over time, noting that progress is often easier to see from the distance.
When Rheumatologists Have Rheumatic Diseases
“I think we learn from medicine everywhere that it is, at its heart, a human endeavor, requiring good science but also a limitless curiosity and interest in your fellow human being, and that the physician-patient relationship is key; all else follows from it.”1 These profound words from Abraham Verghese, MD, MACP, Linda R. Meier…
Advice for New Rheumatology Fellows: Construct Winner’s Triangles
June is always a bittersweet month, at least in academic medicine. We get to look forward to a new fresh set of faces coming into our training programs, but we also have to say goodbye to those once-fresh faces that have progressed through their medical education journeys. These transitions are never easy, neither for the…
Federal Regulatory Actions Against Healthcare Consolidation
In recent months, the U.S. Department of Justice and Federal Trade Commission have started to take action to rein in antitrust behavior, including banning noncompete agreements in the for-profit sector and establishing a taskforce on healthcare monopolies.
HHS Final Rule Reinstates ACA Nondiscrimination Provisions
Effective July 5, discrimination based on race, color, national origin, sex, age and disability by healthcare programs receiving federal assistance is once again prohibited. The application of Section 1557 to all HHS health programs and activities and state and federally facilitated exchanges, which had been weakened by the Trump administration, has been reinstated.
What Rheumatologists Need to Know About Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an acquired thromboinflammatory disease that can have severe, sometimes catastrophic, effects on patients and their families. Our modern understanding of APS began to emerge in the early 1980s. At that point, it was defined as a condition characterized by thrombotic episodes and/or pregnancy complications in the presence of antiphospholipid antibodies (aPL).1…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 803
- Next Page »